Company Analysis
Sign in

Amylyx Pharmaceuticals, Inc. (AMLX)

Nasdaq: AMLX · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.4
◀ Past 5.1● Present 6.3▶ Future 4.8
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

9 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Amylyx Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and 2 in 2023
Applications published
31
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'14'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Amylyx Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
30 published
Amylyx Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in PH)
9 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 11, 202512,246,027Compositions of bile acids and phenylbutyrate compoundsPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Jan 7, 202512,186,330Compositions for improving cell viability and methods of use thereofPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Nov 12, 202412,138,272Methods and compositions for treating amyotrophic lateral sclerosisPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Feb 21, 202311,583,542Compositions of bile acids and phenylbutyrate compoundsPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Jan 24, 202311,559,533Compositions of bile acids and phenylbutyrate compoundsPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Jul 27, 202111,071,742Compositions for improving cell viability and methods of use thereofPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Dec 8, 202010,857,162Compositions for improving cell viability and methods of use thereofPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Apr 9, 201910,251,896Compositions for improving cell viability and methods of use thereofPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Jan 23, 20189,872,865Compositions for improving cell viability and methods of use thereofPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 4, 20252025/0275985COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOFPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Jul 10, 20252025/0222010COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDSPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Feb 20, 20252025/0057856METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Jan 30, 20252025/0032514COMPOSITIONS AND METHODS FOR THE TREATMENT OF VARIOUS DISEASESPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Jan 16, 20252025/0017946COMBINATION OF A BILE ACID AND A PHENYL BUTYRATE COMPOUND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASESPharmaceuticalsAmylyx Pharmaceuticals, Inc.
May 2, 20242024/0139211METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Mar 28, 20242024/0102018OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOFBiotechnologyAmylyx Pharmaceuticals, Inc.
Mar 28, 20242024/0102017OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOFBiotechnologyAmylyx Pharmaceuticals, Inc.
Mar 28, 20242024/0100069Methods and Compositions for Treating Amyotrophic Lateral SclerosisPharmaceuticalsAmylyx Pharmaceuticals, Inc.
Nov 23, 20232023/0372263METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISPharmaceuticalsAmylyx Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AMLX · research, not advice